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A bs tr ac t
Background
The provision of sufficient basal insulin to normalize fasting plasma glucose levels 
may reduce cardiovascular events, but such a possibility has not been formally 
tested.
Methods
We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk 
factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes 
to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per 
deciliter [5.3 mmol per liter]) or standard care and to receive n–3 fatty acids or pla-
cebo with the use of a 2-by-2 factorial design. The results of the comparison between 
insulin glargine and standard care are reported here. The coprimary outcomes were 
nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular 
causes and these events plus revascularization or hospitalization for heart failure. 
Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers 
were also compared between groups.
Results
The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of inci-
dent cardiovascular outcomes were similar in the insulin-glargine and standard-care 
groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary 
outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P = 0.63) and 
5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome 
(hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P = 0.27). New diabetes was diagnosed 
approximately 3 months after therapy was stopped among 30% versus 35% of 1456 
participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; 
P = 0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. 
Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg 
in the standard-care group. There was no significant difference in cancers (hazard 
ratio, 1.00; 95% CI, 0.88 to 1.13; P = 0.97).
Conclusions
When used to target normal fasting plasma glucose levels for more than 6 years, 
insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Al-
though it reduced new-onset diabetes, insulin glargine also increased hypoglycemia 
and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov num-
ber, NCT00069784.)
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A n elevated fasting plasma glucose level is an independent risk factor for ad-verse cardiovascular outcomes.1-7 Basal 
insulin secretion is required to maintain fasting 
plasma glucose levels below 100 mg per deciliter 
(5.6 mmol per liter), and an elevated fasting plasma 
glucose level indicates that there is insufficient 
endogenous insulin secretion to overcome under-
lying insulin resistance.8,9 The correction of this 
deficiency may reduce cardiovascular outcomes.
Such a possibility has not been formally tested; 
however, large outcomes trials of more versus less 
intense glucose lowering in which insulin was 
used in both study groups have not shown a clear 
cardiovascular benefit.7 In addition, one trial 
showed increased mortality.10 These findings, the 
risk of hypoglycemia,11 and suggestions that 
insulin might promote cardiovascular disease or 
cancers12-14 have raised concerns regarding the 
safety of insulin for type 2 diabetes. Conversely, 
extended follow-up of the trial with the biggest 
between-group difference in insulin use until now 
(the United Kingdom Prospective Diabetes Study 
[UKPDS]) revealed a 15% reduction in myocardial 
infarction and a 13% reduction in death among 
people with new-onset type 2 diabetes.15
The UKPDS findings and the potential cardio-
protective effects of insulin16-18 suggest that early 
provision of sufficient basal insulin to normalize 
fasting plasma glucose levels may safely reduce 
incident cardiovascular outcomes. Evidence that 
exogenous insulin may slow the decline in pan-
creatic function with time19-21 suggests that such 
an intervention may also reduce incident diabetes 
in people at risk for the disease. These hypotheses 
were tested in the present study, the Outcome 
Reduction with an Initial Glargine Intervention 
(ORIGIN) trial,22 which involved people 50 years of 
age or older with impaired fasting glucose, im-
paired glucose tolerance, or early type 2 diabetes 
in addition to other cardiovascular risk factors.
Me thods
Study Design and Oversight
The trial tested the effect of titrated basal insulin 
glargine versus standard care and of n–3 fatty-
acid supplements versus placebo on cardiovascular 
outcomes with the use of a 2-by-2 factorial de-
sign.22 The results of the comparison between n–3 
fatty acids and placebo are now reported sepa-
rately in the Journal.23 The study was approved by 
the ethics committee at each study site, and all 
participants provided written informed consent.
A detailed description of the design, eligibility 
criteria, management of disease, and follow-up of 
both treatment groups has been published previ-
ously22 and is summarized in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org. Briefly, participants assigned to 
insulin glargine added an evening injection to their 
glycemic-control regimen and increased the dose 
at least once weekly, targeting a self-measured 
fasting plasma glucose level of 95 mg per deciliter 
(5.3 mmol per liter) or less. Participants who had 
not received a diagnosis of diabetes by the pen-
ultimate study visit reduced the dose of insulin 
by 10 units per day and stopped any metformin by 
the last visit. Participants assigned to standard 
care were treated on the basis of the investiga-
tor’s best judgment and local guidelines. Partici-
pants who had not received a diagnosis of dia-
betes and who were not using glucose-lowering 
drugs by the last visit were scheduled for a 75-g 
oral glucose-tolerance test 3 to 4 weeks later. This 
test was repeated after 10 to 12 weeks (while 
participants continued to not use diabetes med-
ications) if the first test did not establish a diag-
nosis of diabetes.
Outcomes
There were two coprimary composite cardiovas-
cular outcomes. The first was death from cardio-
vascular causes, nonfatal myocardial infarction, or 
nonfatal stroke, and the second was a composite 
of any of these events, a revascularization proce-
dure (cardiac, carotid, or peripheral), or hospital-
ization for heart failure. Other adjudicated out-
comes (defined in the Supplementary Appendix) 
were a composite microvascular outcome, incident 
cases of diabetes in participants without baseline 
diabetes, all-cause mortality, and new or recurrent 
cancers. Hypoglycemic episodes since the previ-
ous visit were recorded at each visit, and weight 
was measured annually.
Trial Conduct and Funding
The mean follow-up period was originally planned 
to be approximately 4 years. This was extended 
by 10 months before recruitment had been com-
pleted. Subsequently, in light of clinical trials re-
ported in 2008 and 200910,24,25 that suggested that 
longer follow-up might be required to detect any 
effect of a glucometabolic intervention and with-
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out any knowledge of treatment effects, the steer-
ing committee extended the trial for 2 years.
Funding, regulatory support, site monitoring, 
drug distribution, and insulin glargine (Lantus) 
were provided by Sanofi, and the n–3 fatty-acid 
supplements and placebo were provided by Pro-
nova BioPharma Norge. The steering committee 
(a list of members is provided in the Supplemen-
tary Appendix), which comprised the joint prin-
cipal investigators, one representative from each 
pharmaceutical company, and the national trial 
leaders from each country, developed the protocol, 
conducted the trial, prepared the manuscript, 
and decided to submit it for publication. Study data 
were collected and independently analyzed by the 
ORIGIN Project Office (led by the joint principal 
investigators, who vouch for the accuracy and 
completeness of the data and the fidelity of the 
study to the protocol), which is based at the Popu-
lation Health Research Institute in Hamilton, 
Ontario, Canada. The full protocol is available at 
NEJM.org.
Statistical Analysis
Data were analyzed with the use of SAS software 
(version 9.1 for Solaris) according to an intention-
to-treat approach described in the protocol and a 
predefined statistical analysis plan. Power calcula-
tions and a description of the role of the data and 
safety monitoring committee are provided in the 
Supplementary Appendix. Time-to-event curves 
were constructed with the use of product-limit 
estimation and were compared with the use of 
stratified log-rank tests. Hazard ratios were cal-
culated with the use of Cox regression models 
stratified according to the factorial allocation, 
baseline diabetes status, and a history of a car-
diovascular event before randomization. For sec-
ondary and other outcomes with fewer than five 
participants with events within any stratum, Cox 
regression models with adjustment for these 
three factors as covariates were used. The propor-
tional-hazards assumption was assessed by test-
ing for the interaction of time with treatment 
group. Incident diabetes from the time of ran-
domization was compared with the use of a Coch-
ran–Mantel–Haenszel test stratified according to 
factorial allocation and a prior cardiovascular 
event, and an odds ratio was calculated. The du-
rability of this effect was explored by repeating 
the analysis after the second post-study oral glu-
cose-tolerance test.
The overall type I error rate of 5% for the two 
coprimary outcomes was partitioned such that the 
first coprimary outcome was tested at a P value 
of 0.044 and the second coprimary outcome was 
tested at a P value of 0.01; the nonadditivity of 
these error rates reflects the correlation between 
these coprimary outcomes. The nominal level of 
significance for all other analyses was P<0.05.
R esult s
Study Population
A total of 12,537 participants (mean age, 63.5 years; 
35% female) were enrolled from 573 cardiology, 
diabetes, or other clinical sites in 40 countries. 
Data from an additional 75 persons at 3 sites were 
excluded while the trial was ongoing at the request 
of national regulatory agencies, after their audits 
of data from these sites. The median follow-up was 
6.2 years (interquartile range, 5.8 to 6.7); at study 
end, the primary-outcome status was known for 
12,443 participants (99%) (Fig. S1 in the Supple-
mentary Appendix). Baseline characteristics are 
shown in Table 1.
insulin use and achieved Fasting Glucose 
Levels
After 1 year, 50% of the insulin-glargine group had 
a fasting plasma glucose level of 94 mg per deci-
liter (5.2 mmol per liter) or less, and that level 
was maintained (Table 2). The median insulin dose 
rose from 0.31 units per kilogram of body weight 
(interquartile range, 0.19 to 0.46) by year 1 to 
0.40 units per kilogram (interquartile range, 0.27 
to 0.56) by year 6 (i.e., 28 units per day in a 70-kg 
person). After 2 years, 5398 participants in the 
insulin-glargine group (90%) were adherent to 
insulin glargine; at 5 years, 4719 (85%) were ad-
herent. At the penultimate visit (i.e., before the 
tapering and discontinuation of insulin in par-
ticipants without diabetes), insulin had been per-
manently discontinued by 19% of the insulin-
glargine group (Table S1 in the Supplementary 
Appendix). At this time, 80% were using any in-
sulin, 35% were not using any oral glucose-low-
ering agents, and 47% were using metformin.
Few participants in the standard-care group 
used insulin during the trial (Table 2). By the end 
of the study, 11% were using insulin, 19% were 
not using oral glucose-lowering agents, 60% were 
using metformin (Table S2 in the Supplementary 
Appendix), and the median fasting plasma glucose 
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level was 123 mg per deciliter (6.8 mmol per liter). 
In addition to this contrast in insulin use, median 
fasting plasma glucose and glycated hemoglobin 
levels were lower in the insulin-glargine group 
than in the standard-care group at 2 years (differ-
ence in fasting plasma glucose, 29 mg per decili-
ter [1.6 mmol per liter]; difference in glycated he-
moglobin, 0.3 percentage points) (Table 2). The use 
of drugs that alter cardiovascular risk and mea-
surements at study end of blood pressure, heart 
rate, waist-to-hip ratio, and lipid levels were simi-
lar in the two groups (Tables S2 and S3 in the 
Supplementary Appendix).
Coprimary Outcomes
The incidence of both coprimary outcomes did 
not differ significantly between treatment groups 
(Fig. 1 and 2), with hazard ratios of 1.02 (95% 
confidence interval [CI], 0.94 to 1.11; P = 0.63) and 
1.04 (95% CI, 0.97 to 1.11; P = 0.27) for the first 
and second coprimary outcomes, respectively. 
There was also no significant difference in mor-
tality (hazard ratio, 0.98; 95% CI, 0.90 to 1.08; 
P = 0.70) or microvascular events (hazard ratio, 
0.97; 95% CI, 0.90 to 1.05; P = 0.43). The effect of 
the intervention on the two coprimary outcomes 
was similar across subgroups (Fig. S2A and S2B 
in the Supplementary Appendix).
Other Outcomes
Among 1456 participants without diabetes at 
randomization (737 assigned to insulin glargine 
and 719 assigned to standard care), those who 
were assigned to insulin glargine were 28% less 
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic
Insulin Glargine
(N = 6264)
Standard Care
(N = 6273)
Demographic and clinical characteristics
Age — yr 63.6±7.8 63.5±7.9
Female sex — no. (%) 2082 (33.2) 2304 (36.7)
Prior cardiovascular event — no. (%)† 3712 (59.3) 3666 (58.4)
Prior myocardial infarction — no. (%) 2221 (35.5) 2208 (35.2)
Prior stroke — no. (%) 805 (12.9) 851 (13.6)
Hypertension — no. (%) 4974 (79.4) 4989 (79.5)
Current smoker — no. (%) 781 (12.5) 771 (12.3)
Any albuminuria — no. (%) 939 (15.0) 985 (15.7)
Ankle–brachial index ≤0.9 — no. (%) 470 (7.5) 501 (8.0)
Glycemic characteristics
Prior diabetes
Use of oral glucose-lowering agent — no. (%) 3748 (59.8) 3692 (58.9)
No use of diabetes drugs — no. (%) 1414 (22.6) 1467 (23.4)
New diabetes — no. (%) 365 (5.8) 395 (6.3)
Impaired glucose tolerance or impaired fasting glucose — no. (%) 735 (11.7) 717 (11.4)
Duration of diabetes — yr 5.5±6.1 5.3±5.9
Fasting plasma glucose — mg/dl
Median 125 124
Interquartile range 109–148 108–148
Glycated hemoglobin — %
Median 6.4 6.4
Interquartile range 5.8–7.2 5.8–7.2
Glycemic drugs
Metformin — no. (%) 1694 (27.0) 1741 (27.8)
Sulfonylurea — no. (%) 1901 (30.3) 1810 (28.9)
Other — no. (%) 173 (2.8) 178 (2.8)
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likely to have diabetes develop from the time of 
randomization until the first oral glucose-tolerance 
test than were participants assigned to standard 
care (i.e., 25% vs. 31% with diabetes, on the basis 
of oral glucose-tolerance tests performed in 64% 
and 65% of eligible participants, respectively; 
odds ratio, 0.72; 95% CI, 0.58 to 0.91; P = 0.006) 
(Fig. S3 in the Supplementary Appendix). When 
persons without diabetes after the first oral glu-
cose-tolerance test underwent a second test a me-
dian of 100 days (interquartile range, 95 to 112) 
after insulin was stopped, additional cases of dia-
betes were detected in both groups (i.e., 30% and 
35% with diabetes, on the basis of oral glucose-
tolerance tests performed in 44% and 47% of eli-
gible participants, respectively; odds ratio, 0.80; 
95% CI, 0.64 to 1.00; P = 0.05). Moreover, when 
cases of diabetes that could not be confirmed by 
the predefined adjudication criteria (i.e., uncertain 
diabetes) were added to those that met the adju-
dication criteria after both oral glucose-tolerance 
tests, the incidence of diabetes was reduced by 
31% (i.e., 35% vs. 43%; odds ratio, 0.69; 95% CI, 
0.56 to 0.86; P = 0.001). Reversion rates to no im-
Table 1. (Continued.)
Characteristic
Insulin Glargine
(N = 6264)
Standard Care
(N = 6273)
Nonglycemic cardiovascular risk factors
Systolic blood pressure — mm Hg 146±22 146±22
Diastolic blood pressure — mm Hg 84±12 84±12
Weight — kg 83.3±16.8 83.1±17.3
Body-mass index‡ 29.8±5.2 29.9±5.3
Waist-to-hip ratio
Men 0.99±0.09 0.98±0.09
Women 0.90±0.09 0.90±0.09
Total cholesterol — mg/dl 190±46 189±46
LDL cholesterol — mg/dl 113±40 112±40
HDL cholesterol — mg/dl 46±12 46±12
Triglycerides — mg/dl
Median 140 142
Interquartile range 98–196 97–195
Creatinine — mg/dl 1.0±0.2 1.0±0.2
Urinary albumin-to-creatinine ratio§
Median 5.2 5.1
Interquartile range 2.5–18.8 2.5–18.6
Other drugs — no. (%)
Statin 3373 (53.8) 3367 (53.7)
Thiazide diuretic 1147 (18.3) 1224 (19.5)
ACE inhibitor or ARB 4330 (69.1) 4351 (69.4)
Beta-blocker 3273 (52.3) 3325 (53.0)
Other blood-pressure drug 2567 (41.0) 2577 (41.1)
Antiplatelet drug 4296 (68.6) 4370 (69.7)
* Plus–minus values are means ±SD. To convert the values for fasting blood glucose to millimoles per liter, multiply by 
0.05551. To convert the values for total, LDL, and HDL cholesterol to millimoles per liter, multiply by 0.02586. To con-
vert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the values for creatinine to mi-
cromoles per liter, multiply by 88.4. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, 
HDL high-density lipoprotein, and LDL low-density lipoprotein.
† Cardiovascular events include myocardial infarction, stroke, and revascularization.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The ratio is based on measurement of albumin in milligrams and creatinine in grams.
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paired fasting glucose and no impaired glucose 
tolerance did not differ significantly between 
groups.
Other analyses showed no significant difference 
in each component of the two coprimary outcomes 
(Fig. 1) or in the incidence of any cancer (hazard 
ratio, 1.00; 95% CI, 0.88 to 1.13; P = 0.97), death 
from cancer (hazard ratio, 0.94; 95% CI, 0.77 to 
1.15; P = 0.52), or cancer at specific sites (Table S4 
in the Supplementary Appendix). There was also 
no significant difference in angina, amputations, 
cardiovascular or noncardiovascular hospitaliza-
tions, motor vehicle accidents, or fractures.
The incidence of a first episode of severe hy-
poglycemia was 1.00 per 100 person-years in the 
insulin-glargine group and 0.31 per 100 person-
years in the standard-care group (P<0.001) (Table 
3). One death attributed to hypoglycemia occurred 
in a participant while taking insulin glargine. The 
incidence of a first episode of nonsevere symp-
tomatic hypoglycemia that was confirmed by a 
self-measured glucose level of 54 mg per deciliter 
(3.0 mmol per liter) or less was 9.83 and 2.68 per 
100 person-years in the insulin-glargine and 
standard-care groups, respectively (P<0.001); the 
incidence of any (i.e., confirmed or uncon-
firmed) nonsevere symptomatic hypoglycemia was 
16.72 and 5.16 per 100 person-years, respectively 
(P<0.001). A total of 2689 participants in the 
insulin-glargine group (43%) and 4693 in the 
standard-care group (75%) did not have any symp-
tomatic hypoglycemia during the ORIGIN trial 
(Table 3). Participants in the insulin-glargine 
group gained a median of 1.6 kg (interquartile 
range, −2.0 to 5.5), and participants in the 
standard-care group lost a median of 0.5 kg 
(interquartile range, −4.3 to 3.2) during a median 
follow-up of 6.2 years.
Discussion
The present trial showed that the early use of bas-
al insulin to target normal fasting plasma glucose 
levels neither reduced nor increased cardiovascular 
outcomes as compared with guideline-suggested 
glycemic control. Moreover, this intervention re-
duced incident diabetes in participants with im-
paired fasting glucose or impaired glucose toler-
ance, though it was associated with modest weight 
gain and more episodes of hypoglycemia. There 
was not an increase in incident cancers; thus, these 
data do not support epidemiologic analyses that 
have linked insulin in general or insulin glargine 
in particular to incident cancers during several 
years of exposure.12,13
Our trial also showed that near-normal fasting 
plasma glucose and glycated hemoglobin levels 
can be achieved and maintained for more than 
6 years with a daily injection of basal insulin with 
or without an oral agent when self-monitored 
fasting glucose levels are used by high-risk patients 
to adjust the dose of insulin glargine. Indeed, fast-
Table 2. Insulin Use and Glycemic Indexes during the Trial.*
Time Insulin Use† Fasting Plasma Glucose Glycated Hemoglobin
Insulin Glargine Standard Care Insulin Glargine Standard Care Insulin Glargine Standard Care
median IQR median IQR median IQR median IQR
number/total number (percent) mg/dl percent
Baseline 6264/6264 (100.0) 0 125 109–148 124 108–148 6.4 5.8–7.2 6.4 5.8–7.2
1 yr 5636/6140 (91.8) 110/6155 (1.8) 93 82–106 NA 5.9 5.5–6.4 6.2 5.7–6.9
2 yr 5398/6019 (89.7) 208/6021 (3.5) 90 79–104 119 103–142 6.0 5.5–6.5 6.3 5.8–6.9
3 yr 5190/5850 (88.7) 305/5871 (5.2) 90 80–103 NA 6.0 5.6–6.6 6.4 5.8–7.0
4 yr 4953/5684 (87.1) 400/5705 (7.0) 91 81–105 NA 6.1 5.7–6.7 6.4 5.9–7.1
5 yr 4719/5522 (85.5) 494/5519 (9.0) 92 81–108 NA 6.2 5.7–6.8 6.5 6.0–7.2
6 yr 3281/3929 (83.5) 392/3925 (10.0) 94 82–110 NA 6.3 5.8–6.9 6.5 6.0–7.2
7 yr 713/853 (83.6) 99/865 (11.4) 94 81–113 NA 6.2 5.8–6.8 6.5 6.0–7.1
* IQR denotes interquartile range, and NA not available. To convert the values for fasting plasma glucose to millimoles per liter, multiply by 
0.05551.
† Participants who attended each visit and who were using insulin glargine (in the insulin-glargine group) or any insulin (in the standard-care 
group) are shown.
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ing plasma glucose levels of less than 95 mg per 
deciliter were achieved and maintained for at least 
5 years in more than 50% of the insulin-glargine 
group, and values of less than 108 mg per deci-
liter (6.0 mmol per liter) were maintained in more 
than 75% of the group. In contrast, participants 
in the standard-care group who used oral agents 
had a median fasting plasma glucose level of 
123 mg per deciliter and glycated hemoglobin 
levels consistent with those recommended in 
clinical-practice guidelines at the end of the study.
Although insulin glargine increased the risk of 
hypoglycemia, the absolute increase in risk was 
low, with approximately 0.7 more severe episodes 
and 11 more suspected or confirmed episodes per 
100 person-years. In contrast, the insulin group 
in the UKPDS had a severe hypoglycemia rate of 
1.8% per year as compared with 0.7% per year in 
controls, representing an absolute difference of 
1.1 percentage points per year.26 This lower rate 
and the observation that 43% of the insulin-
glargine group had no episodes over a median of 
6.2 years may have been due to selection of people 
with mild glucose abnormalities; the use of insu-
lin glargine, which has a long duration of action 
and predictable effect on fasting plasma glucose 
levels; the fact that basal and not prandial insulin 
was used; and the concomitant use of metformin 
in 47% of participants. Nevertheless, the risk of 
hypoglycemia was lower by a factor of approxi-
mately 3 among participants in the standard-care 
group, who had a median weight loss of 0.5 kg, 
as compared with participants in the insulin-
glargine group. Both hypoglycemia and weight 
gain are associated with cardiovascular outcomes 
in epidemiologic studies, so the lack of differences 
in cardiovascular outcomes in our study suggests 
that these adverse effects do not cause outcomes 
or that any harm was offset by benefit.
The intervention with basal insulin glargine 
reduced diabetes incidence, and this occurred 
despite weight gain (which is a known risk factor 
1.0 2.0
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Death from cardiovascular causes
Hospitalization for congestive heart failure
Revascularization
Angina
Unstable
New
Worsening
Limb or digit amputation
Cardiovascular hospitalization
Noncardiovascular hospitalization
Any cancer
Death from cancer
Insulin Glargine
(N=6264)
Hazard Ratio (95% CI)Standard Care
(N=6273)
Outcome
1.04 (0.97–1.11)
0.94 (0.77–1.15)
1.00 (0.88–1.13)
0.99 (0.94–1.05)
0.89 (0.60–1.31)
1.00 (0.94–1.07)
1.02 (0.89–1.16)
0.72 (0.56–0.93)
0.95 (0.85–1.05)
0.91 (0.76–1.08)
1.06 (0.96–1.16)
0.90 (0.77–1.05)
1.00 (0.89–1.13)
1.03 (0.89–1.21)
1.02 (0.88–1.19)
0.97 (0.90–1.05)
0.98 (0.90–1.08)
0.5
1.02 (0.94–1.11)
P Value
2.94
5.52
3.87
2.57
0.93
0.91
1.57
0.85
2.69
2.07
0.66
0.27
1.29
0.13
6.98
7.90
1.32
0.51
0.63
0.27
0.43
0.70
0.75
0.69
0.98
0.16
0.24
0.29
0.28
0.01
0.80
0.55
0.90
0.85
0.97
0.52
no. (%)
1041 (16.6)
1792 (28.6)
1323 (21.1)
  951 (15.2)
336 (5.4)
331 (5.3)
580 (9.3)
310 (4.9)
  908 (14.5)
  709 (11.3)
238 (3.8)
100 (1.6)
455 (7.3)
  47 (0.8)
2081 (33.2)
2339 (37.3)
476 (7.6)
189 (3.0)
no./100
patient-yr
2.85
5.28
3.99
2.60
0.90
0.88
1.55
0.95
2.52
2.17
0.72
0.38
1.26
0.14
6.91
7.93
1.32
0.54
no. (%)
1013 (16.1)
1727 (27.5)
1363 (21.7)
  965 (15.4)
326 (5.2)
319 (5.1)
576 (9.2)
343 (5.5)
  860 (13.7)
  743 (11.8)
261 (4.2)
138 (2.2)
446 (7.1)
  53 (0.8)
2071 (33.0)
2349 (37.4)
477 (7.6)
201 (3.2)
no./100
patient-yr
Figure 1. Hazard Ratios for the Coprimary and Other Outcomes.
Hazard ratios are adjusted for the factorial allocation, baseline diabetes status, and the presence or absence of a history of a cardiovascular 
event before randomization, as described in the protocol.
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for diabetes). The reduction in incident diabetes is 
unlikely to be due to the masking of hyperglycemia 
by residual injected insulin glargine, because the 
mean duration of action is approximately 1 day.27 
It is also unlikely to be due to concomitant met-
formin, because less metformin was used in the 
insulin-glargine group than in the standard-care 
group. Whether the decrease in incident diabetes 
will lead to long-term clinical benefits is unknown. 
Nevertheless, the finding supports further research 
into the effect of insulin regimens on endocrine 
pancreatic function.
The current trial had several strengths. A large 
difference in insulin therapy was achieved and 
maintained between groups. The trial duration of 
more than 6 years, the high rates of follow-up and 
treatment adherence, the large number of cardio-
vascular outcomes, and the prospective collection 
and adjudication of these outcomes ensured suffi-
cient power to detect a clinically important short-
term or medium-term cardiovascular effect. In 
addition, the prospective collection of data per-
taining to hypoglycemia, weight gain, and cancers 
ensured that potential harms were detected and 
quantified.
Limitations of the study include the fact that 
metformin was ultimately used by 47% of the 
insulin-glargine group. Evidence that metformin 
is cardioprotective14,15,28 raises the possibility that 
any cardiovascular harm of insulin may have been 
mitigated by metformin. However, any benefit of 
metformin would have also applied to the 60% 
of the standard-care group who used metformin. 
Second, the ORIGIN trial involved people who 
are not normally prescribed insulin and in whom 
insulin glargine was used to achieve fasting 
plasma glucose levels much lower than those 
typically achieved with insulin therapy. However, 
the effect in participants with and those without 
diabetes was similar. Finally, the ORIGIN trial 
was designed to test the effect of using titrated 
basal insulin to control glucose levels versus 
standard care with guideline-suggested degrees 
of glycemic control. The ORIGIN trial was spe-
cifically not designed to test more intense versus 
less intense glucose lowering. As a large differ-
ence in insulin use was achieved (vs. a small 
difference in glycemic control), these findings 
are most relevant to the effect of insulin therapy 
and not the effect of glucose lowering on cardio-
vascular or microvascular outcomes, which has 
been studied in other trials.7,10,15,24,25
Finally, no previously unrecognized adverse 
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Figure 2. Proportion of Participants with Events over Time.
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effects of basal insulin were identified during 
careful follow-up for a median of 6.2 years; hy-
poglycemia rates were low and weight gain mod-
est. This suggests that the main clinical use of 
insulin is as a flexible glucose-lowering drug and 
that previously reported cardiovascular benefits 
in type 129 and type 2 7,15 diabetes may have been 
mediated through metabolic effects rather than 
direct cardiovascular effects.
In summary, therapy with basal insulin glar-
gine for more than 6 years had a neutral effect on 
cardiovascular outcomes and cancers. Moreover, 
this therapy maintained near-normal glycemic 
control and slowed progression of dysglycemia, 
but it was associated with a modest increase in 
hypoglycemic episodes and in weight. Whether 
the glycemic benefit will affect future microvas-
cular or other outcomes remains unknown. In 
the meantime, the findings of the ORIGIN trial 
do not support changing standard therapies for 
early dysglycemia.
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Table 3. Incidence of a First Episode of Severe Hypoglycemia.
Variable
Insulin Glargine
(N = 6264)
Standard Care
(N = 6273) P Value
Severe hypoglycemia*
Participants with ≥1 episode — no. (no./100 person-yr) 359 (1.00) 113 (0.31) <0.001
Total episodes during follow-up — no. 457 134
Confirmed nonsevere symptomatic hypoglycemia†
Participants with ≥1 episode — no. (no./100 person-yr) 2614 (9.83) 904 (2.68) <0.001
Episodes/yr in participants with ≥1 episode — median (interquartile 
range)
0.5 (0.2–1.4) 0.3 (0.2–0.8) <0.001
Participants with no confirmed episodes during follow-up — no. (%) 3650 (58.3) 5369 (85.6) <0.001
Any nonsevere symptomatic hypoglycemia
Participants with ≥1 episode — no. (no./100 person-yr) 3575 (16.72) 1580 (5.16) <0.001
Episodes/yr in participants with ≥1 episode — median (interquartile 
range)
1.1 (0.4–3.1) 0.5 (0.2–1.3) <0.001
Participants with no episodes during follow-up — no. (%) 2689 (42.9) 4693 (74.8) <0.001
* This category included any episode of hypoglycemia for which the patient required assistance and that was confirmed by a 
self-measured or laboratory plasma glucose level of 2 mmol per liter (36 mg per deciliter) or less or from which the pa-
tient recovered promptly after oral carbohydrate, intravenous glucose, or glucagon administration.
† This category included any symptomatic nonsevere hypoglycemic episode that was confirmed by a self-measured glucose 
level of 3 mmol per liter (54 mg per deciliter) or less.
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